Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Non-Current Assets (2016 - 2026)

Oramed Pharmaceuticals filings provide 12 years of Other Non-Current Assets readings, the most recent being $44000.0 for Q4 2025.

  • Quarterly Other Non-Current Assets rose 2100.0% to $44000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44000.0 through Dec 2025, up 2100.0% year-over-year, with the annual reading at $44000.0 for FY2025, 2100.0% up from the prior year.
  • Other Non-Current Assets hit $44000.0 in Q4 2025 for Oramed Pharmaceuticals, up from $2000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $111.5 million in Q4 2022 and bottomed at $2000.0 in Q2 2024.
  • Average Other Non-Current Assets over 5 years is $9.4 million, with a median of $7000.0 recorded in 2023.
  • The largest annual shift saw Other Non-Current Assets tumbled 99.99% in 2023 before it skyrocketed 2100.0% in 2025.
  • Oramed Pharmaceuticals' Other Non-Current Assets stood at $11.0 million in 2021, then skyrocketed by 909.72% to $111.5 million in 2022, then tumbled by 99.99% to $7000.0 in 2023, then plummeted by 71.43% to $2000.0 in 2024, then skyrocketed by 2100.0% to $44000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Other Non-Current Assets are $44000.0 (Q4 2025), $2000.0 (Q3 2025), and $38000.0 (Q2 2025).